Inflammation causes colorectal cancer because of the loss of this protein

Share This Post

Chronic inflammation is a  predisposing factor for colorectal cancer, which is the third leading cause of cancer-related deaths in the United States. Dr. Anna Means and colleagues reported in the journal Cell and Molecular Gastroenterology and Hepatology last month that they linked the inflammation-driven  carcinogenesis of the colon to the loss of an important signaling protein called SMAD4. SMAD4 is part of the transforming growth factor β (TGF-β) signaling pathway, which regulates the immune and inflammatory response to infection in the colonic epithelium.

The specific deletion of SMAD4 gene in normal mouse colon epithelial cells grown in vivo increased the expression of inflammatory  mediators. In adult mice with inflammation, the lack of SMAD4 results in a surprising similarity between tumors and cancers associated with human colitis.

Loss of SMAD4 was also observed in 48% of human colitis-related cancers, compared with 19% of scattered colorectal cancers. “This loss may be an important factor from premalignant lesions to aggressive malignant tumors,” the researchers concluded. Therefore, friends with chronic inflammation must eliminate inflammation in time, and do not regret it until the inflammation develops into cancer.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

CAR T Cell therapy in Mumbai, India
CAR T-Cell therapy

CAR T-Cell therapy in Mumbai, India

CAR T-cell therapy, an advanced cancer treatment, is now available in Mumbai, offering hope to those suffering from some types of blood cancers. This therapy modifies a patient’s T-cells to seek out and destroy cancer cells. It is being offered by many of the leading medical centers in Mumbai, enhancing survival rates and quality of life. With advanced technology and oncologists, Mumbai is slowly becoming a hub for CAR T-cell therapy in India.

LungVax lung cancer vaccine
Lung cancer

LungVax: Lung cancer vaccine

LungVax is an innovative lung cancer vaccine designed to stimulate the immune system to target and destroy cancer cells. It is engineered to enhance the body’s natural defense mechanisms against tumor growth, offering a novel approach to lung cancer treatment. LungVax aims to prevent recurrence in high-risk patients and improve survival rates, marking a promising development in immunotherapy for one of the deadliest forms of cancer.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy